S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
NASDAQ:FULC

Fulcrum Therapeutics (FULC) Stock Price, News & Analysis

$6.84
-0.22 (-3.12%)
(As of 04/19/2024 ET)
Today's Range
$6.67
$7.28
50-Day Range
$6.84
$12.00
52-Week Range
$2.43
$13.70
Volume
555,199 shs
Average Volume
531,317 shs
Market Capitalization
$423.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.17

Fulcrum Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
92.5% Upside
$13.17 Price Target
Short Interest
Healthy
3.65% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.71mentions of Fulcrum Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$57,240 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.76) to ($1.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.04 out of 5 stars

Medical Sector

352nd out of 909 stocks

Pharmaceutical Preparations Industry

156th out of 424 stocks

FULC stock logo

About Fulcrum Therapeutics Stock (NASDAQ:FULC)

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

FULC Stock Price History

FULC Stock News Headlines

Biden replacement revealed?
A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.
FULC Apr 2024 9.000 put
Biden replacement revealed?
A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.
FULC Jun 2024 15.000 call
Earnings Preview: Fulcrum Therapeutics
See More Headlines
Receive FULC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/21/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:FULC
Fax
N/A
Employees
76
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.17
High Stock Price Target
$17.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+92.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-97,330,000.00
Net Margins
-3,470.05%
Pretax Margin
-3,470.05%

Debt

Sales & Book Value

Annual Sales
$2.81 million
Book Value
$3.80 per share

Miscellaneous

Free Float
60,387,000
Market Cap
$423.64 million
Optionable
Optionable
Beta
2.29
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Alexander C. Sapir (Age 57)
    CEO, President & Director
  • Dr. Bradley E. Bernstein M.D.
    Ph.D., Founder
  • Dr. Michael R. Green
    Founder
  • Dr. Rudolf Jaenisch M.D.
    Ph.D., Founder
  • Dr. Tsun-Huei Lee M.D. (Age 60)
    Ph.D., Founder
  • Dr. Danny Reinberg
    Founder
  • Mr. Alan A. Musso C.M.A. (Age 62)
    CPA, Chief Financial Officer
  • Mr. Gregory Tourangeau
    Controller & Principal Accounting Officer
  • Dr. Jeffrey W. Jacobs Ph.D. (Age 61)
    Chief Scientific Officer
  • Mr. Curtis G. Oltmans J.D. (Age 61)
    Senior VP, Chief Legal Officer & Corporate Secretary
    Comp: $83.98k

FULC Stock Analysis - Frequently Asked Questions

Should I buy or sell Fulcrum Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fulcrum Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" FULC shares.
View FULC analyst ratings
or view top-rated stocks.

What is Fulcrum Therapeutics' stock price target for 2024?

6 brokers have issued 12 month price objectives for Fulcrum Therapeutics' shares. Their FULC share price targets range from $6.00 to $17.00. On average, they expect the company's share price to reach $13.17 in the next year. This suggests a possible upside of 92.5% from the stock's current price.
View analysts price targets for FULC
or view top-rated stocks among Wall Street analysts.

How have FULC shares performed in 2024?

Fulcrum Therapeutics' stock was trading at $6.75 at the beginning of 2024. Since then, FULC stock has increased by 1.3% and is now trading at $6.84.
View the best growth stocks for 2024 here
.

Are investors shorting Fulcrum Therapeutics?

Fulcrum Therapeutics saw a decline in short interest in March. As of March 31st, there was short interest totaling 2,260,000 shares, a decline of 5.4% from the March 15th total of 2,390,000 shares. Based on an average daily volume of 668,800 shares, the days-to-cover ratio is currently 3.4 days.
View Fulcrum Therapeutics' Short Interest
.

When is Fulcrum Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our FULC earnings forecast
.

How were Fulcrum Therapeutics' earnings last quarter?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) issued its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $0.04. The company earned $0.87 million during the quarter, compared to the consensus estimate of $0.65 million. Fulcrum Therapeutics had a negative trailing twelve-month return on equity of 36.65% and a negative net margin of 3,470.05%.

What ETFs hold Fulcrum Therapeutics' stock?

ETFs with the largest weight of Fulcrum Therapeutics (NASDAQ:FULC) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Simplify Health Care ETF (PINK) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

What other stocks do shareholders of Fulcrum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulcrum Therapeutics investors own include VIVUS (VVUS), Provention Bio (PRVB), Entasis Therapeutics (ETTX), Kaleido Biosciences (KLDO), VBI Vaccines (VBIV), Xeris Biopharma (XERS), CymaBay Therapeutics (CBAY), Evelo Biosciences (EVLO) and Akero Therapeutics (AKRO).

When did Fulcrum Therapeutics IPO?

Fulcrum Therapeutics (FULC) raised $76 million in an IPO on Thursday, July 18th 2019. The company issued 4,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink acted as the underwriters for the IPO.

Who are Fulcrum Therapeutics' major shareholders?

Fulcrum Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Mass General Brigham Inc (0.33%) and Denali Advisors LLC (0.04%). Insiders that own company stock include Christopher Morabito, Curtis Gale Oltmans, Greg Tourangeau, James A Geraghty, Peter G Thomson, Ra Capital Management, LP, Robert J Gould and Robert J Gould.
View institutional ownership trends
.

How do I buy shares of Fulcrum Therapeutics?

Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FULC) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners